Menu
Dr. Suzuki brings 33 years of experience in both outpatient and inpatient psychiatric care to Innovative Psychiatric Services. For over 4 years, he has been treating patients with SPRAVATO at an outpatient treatment center at Las Encinas Hospital, where he has served as the Medical Director since 2005. Dr. Suzuki also serves as an Adjunct Assistant Clinical Professor of Psychiatry at USC Keck School of Medicine’s Department of Psychiatry and is a valued partner of San Marino Psychiatric Associates. He earned his undergraduate degree from Stanford University, his medical degree from Northwestern University, and completed his Psychiatry Residency at UCLA Sepulveda.
David supervises the clinical operations and staff training at Innovative Psychiatric Services, with a passion for compassionate care and a mission to help patients reach their goals. He earned his Psychiatric Nurse Practitioner degree from Azusa Pacific University. In addition to his outpatient practice, David has gained extensive inpatient psychiatric experience at Loma Linda Behavioral Health Hospital, Charter Oaks Hospital, and Las Encinas Hospital.
SPRAVATO – In 2019, the FDA grantedapproval for Spravato (Esketamine) totreat Treatment Resistant Depression (TRD). Initially approved as an anesthetic agent in 1970, ketamine was later discovered to have a rapid and potent antidepressant effect when administered intravenously. Notably, Spravato is an intranasal formulation, that is patient administered under supervision. It became the first and only form of ketamine approved for use in treating depression. To find out more visit: